The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market During 2026–2030? _x000D_
The next-generation sequencing (ngs)-based molecular diagnostics market size has demonstrated significant expansion over recent years. It is projected to increase from $2.26 billion in 2025 to $2.43 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. This historical growth can be ascribed to several factors, including an increase in genetic disorder testing, the evolution of high-throughput sequencing, growing public awareness of molecular diagnostics, its widespread adoption in clinical labs, and continuous technological enhancements in sequencing reagents._x000D_
_x000D_
The next-generation sequencing (ngs)-based molecular diagnostics market size is predicted to undergo significant expansion over the next few years. It is forecasted to reach $3.23 billion in 2030, advancing at a compound annual growth rate (CAGR) of 7.3%. This anticipated growth can be ascribed to several factors, including the integration of AI and machine learning within diagnostics, the broadening of cloud-based genomic platforms, the development of portable and point-of-care sequencing devices, an increase in personalized medicine applications, and collaborations formed between diagnostics and biotech firms. Prominent trends for the forecast period feature AI-assisted molecular diagnostics, cloud genomic analysis platforms, portable sequencing devices, the integration of bioinformatics pipelines, and the rapid detection of disease markers._x000D_
_x000D_
#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_
_x000D_
Which Factors Are Influencing The Growth Of The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?_x000D_
The increasing occurrence of infectious diseases is projected to boost the next-generation sequencing (NGS)-based molecular diagnostics market. Infectious diseases are conditions resulting from microorganisms such as bacteria, viruses, fungi, or parasites that enter the body, multiply, and interfere with normal functions. The spread of these diseases is accelerating due to rising travel and migration, which facilitate the transmission of pathogens across different areas. Next-generation sequencing (NGS)-based molecular diagnostics assists in detecting infectious diseases by offering comprehensive and precise analysis of pathogens. It helps reduce the time needed for diagnosis by simultaneously identifying multiple microorganisms, thereby improving treatment accuracy and patient care. As an illustration, the UK Health Security Agency stated in February 2024 that tuberculosis cases in England escalated to 4,850 in 2023, representing a 10.7% increase from 4,380 cases recorded in 2022. Therefore, the rising incidence of infectious diseases is a primary catalyst for the expansion of the next-generation sequencing (NGS)-based molecular diagnostics market._x000D_
_x000D_
How Is Segmentation Applied In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Segment Analysis?_x000D_
The next-generation sequencing (ngs)-based molecular diagnostics market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits_x000D_
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications_x000D_
3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware_x000D_
2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents_x000D_
3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services_x000D_
4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays_x000D_
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits_x000D_
_x000D_
Which Trends Are Influencing Demand In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?_x000D_
Companies operating within the next-generation sequencing (NGS)-based molecular diagnostics market are prioritizing the creation of advanced NGS-based panels to elevate the precision, accessibility, and efficacy of genetic testing. NGS panels are specific gene or genomic region sets analyzed concurrently using NGS technology to uncover clinically pertinent mutations for swifter and more accurate molecular diagnostics. For instance, in April 2024, Pillar Biosciences, a US-based diagnostics company, obtained FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which identifies 22 clinically relevant genes in one multiplex reaction. Developed for use with Illumina’s MiSeq Dx system, this panel facilitates a sample-to-report time of approximately 48 hours and can manage up to 46 clinical samples per run. OncoReveal CDx also features companion diagnostic claims for KRAS (for EGFR-targeted therapy in colorectal cancer) and EGFR (TKI therapy in non–small-cell lung cancer), thereby allowing for more comprehensive and streamlined detection of actionable genomic alterations to improve clinical decision-making._x000D_
_x000D_
Who Are The Companies Participating In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Environment?_x000D_
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB _x000D_
_x000D_
#Get The Full Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report:#_x000D_
_x000D_
Which Region Holds The Highest Market Share In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?_x000D_
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request A Customized Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report For Competitive Insights:#_x000D_
_x000D_
#Browse Through More Reports Similar to the Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market 2026, By The Business Research Company#_x000D_
_x000D_
Ngs Based Rna Sequencing Market Report 2026_x000D_
_x000D_
Next Generation Sequencing Market 2026_x000D_
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-market_x000D_
_x000D_
Point Of Care Molecular Diagnostics Market Report 2026_x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model